Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Protalix BioTherapeutics, Inc., a pioneering biopharmaceutical company, is set to present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. Dror Bashan, the President and CEO, will deliver the presentation at 3:30 p.m. EDT at the Lotte New York Palace Hotel. The event, which runs from September 8-10, will also feature management participating in one-on-one meetings with investors.

Headquartered in Carmiel, Israel, Protalix specializes in the development and commercialization of recombinant therapeutic proteins produced via its proprietary ProCellEx® plant cell-based expression system. The company is notable for being the first to receive FDA approval for a protein produced through a plant cell-based expression system. One of its flagship products, taliglucerase alfa, developed for the treatment of Gaucher disease, is licensed to Pfizer, except in Brazil where Protalix retains full rights.

Protalix made headlines in May 2023 with the FDA and EMA approvals of its second product, Elfabrio®, which is being developed in partnership with Chiesi Farmaceutici S.p.A. Additionally, the company is advancing its pipeline with several promising candidates, including PRX–115, a recombinant PEGylated uricase aimed at treating uncontrolled gout, and PRX–119, a long-acting DNase I therapy for NETs-related diseases, among others.

As Protalix BioTherapeutics continues to innovate with its unique plant cell-based production technology, its participation in this high-profile investment conference positions the company to attract investor interest and bolster its commercial opportunities in the biopharmaceutical landscape.

Protalix BioTherapeutics, Inc. (PLX) is making a significant stride in its growth trajectory by presenting at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025. This is an essential opportunity for the company to showcase its innovative plant cell-based protein expression technology, ProCellEx, and highlight its recent achievements, including FDA approvals for both taliglucerase alfa and Elfabrio.

Given Protalix's unique position as the first company to receive FDA approval for a protein produced through a plant cell-based system, investor interest could intensify, particularly as the biopharmaceutical sector continues to show resilience and potential for growth. The company’s partnerships with major players like Pfizer and Chiesi Farmaceutici affirm its credibility and market reach. As Protalix engages in one-on-one meetings with potential investors during the conference, it will be crucial for them to articulate their development pipeline, which includes promising candidates like PRX-115 and PRX-119.

Despite these advantages, investors should be cautious. The biopharmaceutical industry often faces volatility due to regulatory outcomes, competitive pressures, and market dynamics. Protalix's current stock performance should be monitored closely, especially around the time of the conference, as investor sentiment and market perception can shift rapidly based on news flow from such engagements.

In conclusion, for investors considering entering or expanding their position in Protalix BioTherapeutics, this conference could serve as a potential catalyst for stock movement. Interest in Protalix would ideally align with a well-defined risk assessment, taking into account its innovative therapeutic prospects against the inherent risks of the biopharmaceutical landscape. Keeping track of the feedback and investor interactions from the conference will provide valuable insights into the company's market positioning and future potential.